Recombinant human antibody to Human CSF2
Figure 1 GM-CSF blockade helps control CART19 toxicities and may improve efficacy.
A) CART19 and lenzilumab treated CART19 and lenzilumab treated CART19 are equally effective in survival outcomes in a high tumor burden NALM6 relapse model compared to UTD (untransduced T cells) (7-8 mice per group, n=2) B-D) Lenzilumab & anti-mouse GM-CSF antibody controlled CRS induced weight loss, neutralized serum human GM-CSF, and reduced expression of serum mouse MCP-1 (monocyte chemoattractant protein-1) in a primary ALL xenograft CART19 CRS/NT model (3 mice per group, * p<0.05). E) Lenzilumab & anti-mouse GM-CSF antibody reduced brain inflammation as shown by MRI in a primary ALL XENOGRAFT CART19 CRS/NT model (3 mice per group, * p<0.05, ** p<0.01).F-G) CART19 + Lenzilumab & anti-mouse GM-CSF antibody treated mice showed reduced CD19+ brain leukemic burden and reduced percentage of brain macrophages in a primary ALL xenograft CART19 CRS/NT model (3 mice per group) H) CRISPR Cas9 K/O of GM-CSF reduces its expression via intracellular staining in CART19 and UTD with NALM6 stimulation.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Lenzilumab.
Afuco™ Anti-CSF2 ADCC Therapeutic Antibody (Lenzilumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human CSF2.
For Research Use Only. Not For Clinical Use.